Kairos Pharma’s (KAPA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report sent to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

Kairos Pharma Trading Up 8.8 %

Shares of Kairos Pharma stock opened at $1.24 on Wednesday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.